within Pharmacolibrary.Drugs.ATC.M;

model M01AB17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Bufexamac is a topical non-steroidal anti-inflammatory drug (NSAID) previously used for the treatment of dermatological conditions such as eczema and dermatitis. It functions by inhibiting cyclooxygenase enzymes and thereby reducing prostaglandin synthesis. Bufexamac has been withdrawn or banned in several countries due to reports of severe contact dermatitis; it is not approved for use in most jurisdictions today.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies are available for bufexamac, and all parameters herein are rough estimates based on its typical use as a topical preparation for adults.</p><h4>References</h4><ol><li><p>Larson, DL, &amp; Lombardino, JG (1980). The topical anti-inflammatory effects of piroxicam in rodents. <i>Agents and actions</i> 10(3) 246–251. DOI:<a href=&quot;https://doi.org/10.1007/BF02025943&quot;>10.1007/BF02025943</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7405751/&quot;>https://pubmed.ncbi.nlm.nih.gov/7405751</a></p></li><li><p>Trommer, H, &amp; Neubert, RH (2005). Screening for new antioxidative compounds for topical administration using skin lipid model systems. <i>Journal of pharmacy &amp; pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</i> 8(3) 494–506. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16401395/&quot;>https://pubmed.ncbi.nlm.nih.gov/16401395</a></p></li><li><p>Brogden, RN, et al., &amp; Avery, GS (1975). Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. <i>Drugs</i> 10(5-6) 351–356. DOI:<a href=&quot;https://doi.org/10.2165/00003495-197510050-00005&quot;>10.2165/00003495-197510050-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1204506/&quot;>https://pubmed.ncbi.nlm.nih.gov/1204506</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01AB17;
